Smartleaf Asset Management LLC Has $28,000 Stake in Fresenius Medical Care AG (NYSE:FMS)

Smartleaf Asset Management LLC grew its position in Fresenius Medical Care AG (NYSE:FMS) by 192.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,224 shares of the company’s stock after purchasing an additional 806 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Fresenius Medical Care were worth $28,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. US Bancorp DE grew its position in shares of Fresenius Medical Care by 8.6% in the fourth quarter. US Bancorp DE now owns 20,429 shares of the company’s stock valued at $463,000 after purchasing an additional 1,610 shares during the last quarter. QRG Capital Management Inc. grew its position in Fresenius Medical Care by 16.7% during the fourth quarter. QRG Capital Management Inc. now owns 67,973 shares of the company’s stock worth $1,539,000 after buying an additional 9,706 shares in the last quarter. Bank of New York Mellon Corp grew its position in Fresenius Medical Care by 5.8% during the fourth quarter. Bank of New York Mellon Corp now owns 21,951 shares of the company’s stock worth $497,000 after buying an additional 1,205 shares in the last quarter. Arbor Investment Advisors LLC acquired a new stake in Fresenius Medical Care during the fourth quarter worth approximately $200,000. Finally, Callan Capital LLC acquired a new stake in Fresenius Medical Care during the fourth quarter worth approximately $297,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analysts Set New Price Targets

FMS has been the topic of a number of analyst reports. Truist Financial increased their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Trading Down 0.8 %

Shares of FMS stock opened at $24.18 on Thursday. The stock’s fifty day moving average price is $23.61 and its two-hundred day moving average price is $22.13. The company has a market cap of $14.19 billion, a PE ratio of 19.98, a P/E/G ratio of 0.76 and a beta of 0.99. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $25.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.